An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928) - Planchard, D; Besse, B; Groen, H J (J Clin Oncol, 2016)
(Suppl): abstract 107